Global Custom Market Research Reports Provider Company

phone

Alzheimers Disease - Pipeline Review, H2 2018

  • Published Date: 07 Aug 2018
  • Number of Pages: 1333
  • Category: Pharmaceuticals
  • Country: Global
Alzheimers Disease - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2018, provides an overview of the Alzheimers Disease (Central Nervous System) pipeline landscape.

Alzheimers disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Alzheimers Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alzheimers Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimers Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimers Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 25, 56, 53, 3, 276, 102 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 41 molecules, respectively.

Alzheimers Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimers Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimers Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimers Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimers Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimers Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimers Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimers Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct


Introduction 11
Alzheimers Disease - Overview 12
Alzheimers Disease - Therapeutics Development 13
Alzheimers Disease - Therapeutics Assessment 80
Alzheimers Disease - Companies Involved in Therapeutics Development 107
Alzheimers Disease - Drug Profiles 201
Alzheimers Disease - Dormant Projects 1212
Alzheimers Disease - Discontinued Products 1251
Alzheimers Disease - Product Development Milestones 1258
Appendix 1270

List Of Tables

List of Tables
Number of Products under Development for Alzheimers Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Alzheimers Disease - Pipeline by AB Science SA, H2 2018
Alzheimers Disease - Pipeline by AbbVie Inc, H2 2018
Alzheimers Disease - Pipeline by AC Immune SA, H2 2018
Alzheimers Disease - Pipeline by Accera Inc, H2 2018
Alzheimers Disease - Pipeline by Actinogen Medical Ltd, H2 2018
Alzheimers Disease - Pipeline by Acumen Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Addex Therapeutics Ltd, H2 2018
Alzheimers Disease - Pipeline by Aequus Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Affichem SA, H2 2018
Alzheimers Disease - Pipeline by AFFiRiS AG, H2 2018
Alzheimers Disease - Pipeline by Alector LLC, H2 2018
Alzheimers Disease - Pipeline by Allergan Plc, H2 2018
Alzheimers Disease - Pipeline by Allgenesis Biotherapeutics Inc, H2 2018
Alzheimers Disease - Pipeline by Allinky Biopharma SL, H2 2018
Alzheimers Disease - Pipeline by ALSP Inc, H2 2018
Alzheimers Disease - Pipeline by Alzhyme Pty Ltd, H2 2018
Alzheimers Disease - Pipeline by Alzinova AB, H2 2018
Alzheimers Disease - Pipeline by AlzProtect SAS, H2 2018
Alzheimers Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Alzheimers Disease - Pipeline by Amgen Inc, H2 2018
Alzheimers Disease - Pipeline by Anavex Life Sciences Corp, H2 2018
Alzheimers Disease - Pipeline by Annexon Inc, H2 2018
Alzheimers Disease - Pipeline by Aphios Corp, H2 2018
Alzheimers Disease - Pipeline by Apodemus AB, H2 2018
Alzheimers Disease - Pipeline by Applied Research using OMIC Sciences SL, H2 2018
Alzheimers Disease - Pipeline by Araclon Biotech SL, H2 2018
Alzheimers Disease - Pipeline by Archer Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by ArmaGen Inc, H2 2018
Alzheimers Disease - Pipeline by Asceneuron SA, H2 2018
Alzheimers Disease - Pipeline by AstraZeneca Plc, H2 2018
Alzheimers Disease - Pipeline by Aucta Pharmaceuticals LLC, H2 2018
Alzheimers Disease - Pipeline by Auritec Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Axon Neuroscience SE, H2 2018
Alzheimers Disease - Pipeline by Axovant Sciences Ltd, H2 2018
Alzheimers Disease - Pipeline by Axsome Therapeutics Inc, H2 2018
Alzheimers Disease - Pipeline by Axxam SpA, H2 2018
Alzheimers Disease - Pipeline by AZTherapies Inc, H2 2018
Alzheimers Disease - Pipeline by Bactevo Ltd, H2 2018
Alzheimers Disease - Pipeline by Beactica AB, H2 2018
Alzheimers Disease - Pipeline by Berg LLC, H2 2018
Alzheimers Disease - Pipeline by BioArctic AB, H2 2018
Alzheimers Disease - Pipeline by Biogen Inc, H2 2018
Alzheimers Disease - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
Alzheimers Disease - Pipeline by BioHealthonomics Inc, H2 2018
Alzheimers Disease - Pipeline by BioXcel Therapeutics Inc, H2 2018
Alzheimers Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Alzheimers Disease - Pipeline by Bolder Biotechnology Inc, H2 2018
Alzheimers Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018
Alzheimers Disease - Pipeline by Bristol-Myers Squibb Co, H2 2018
Alzheimers Disease - Pipeline by Bsim2, H2 2018
Alzheimers Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2018
Alzheimers Disease - Pipeline by Cardax Inc, H2 2018
Alzheimers Disease - Pipeline by Carna Biosciences Inc, H2 2018
Alzheimers Disease - Pipeline by Celon Pharma SA, H2 2018
Alzheimers Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2018
Alzheimers Disease - Pipeline by Clera Inc, H2 2018
Alzheimers Disease - Pipeline by Cognition Therapeutics Inc, H2 2018
Alzheimers Disease - Pipeline by Cognosci Inc, H2 2018
Alzheimers Disease - Pipeline by CohBar Inc, H2 2018
Alzheimers Disease - Pipeline by Corium International Inc, H2 2018
Alzheimers Disease - Pipeline by Coronis NeuroSciences Ltd, H2 2018
Alzheimers Disease - Pipeline by Cortice Biosciences Inc, H2 2018
Alzheimers Disease - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Alzheimers Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Alzheimers Disease: Competitive Landscape to 2026 Alzheimers disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in

View Report

Alzheimers Disease - Pipeline Review, H2 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2018, provides an overview of the Alzheimers Disease

View Report

The global market size of Alzheimers Drug is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports